Price chart
Loading 1Y daily…
Financial overlay · last 12 quarters
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-01-31 | $0.8B | $0.2B | $0.2B | $0.1B | 29.2% | 29.4% |
| 2025-10-31 | $0.8B | $0.2B | $0.2B | $0.2B | 29.1% | 29.7% |
| 2025-07-31 | $0.8B | $0.2B | $0.2B | $0.2B | 25.4% | 24.8% |
| 2025-04-30 | $0.8B | $0.2B | $0.2B | $0.9B | 30.1% | 30.8% |
| 2025-01-31 | $0.7B | $0.2B | $0.2B | $0.1B | 27.1% | 26.1% |
| 2024-10-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Earnings replay · last 20 reports
| Date | EPS actual | EPS est | Surprise |
|---|---|---|---|
| 2026-03-04 | 2.06 | 1.94 | +6.5% |
| 2025-11-20 | 2.04 | 1.95 | +4.5% |
| 2025-08-27 | 1.99 | 1.90 | +4.8% |
| 2025-05-28 | 1.97 | 1.74 | +13.0% |
| 2025-03-05 | 1.74 | 1.58 | +10.1% |
| 2024-12-05 | 1.75 | 1.58 | +10.7% |
| 2024-08-28 | 1.62 | 1.53 | +5.6% |
| 2024-05-30 | 1.50 | 1.42 | +5.3% |
| 2024-02-29 | 1.38 | 1.30 | +6.2% |
| 2023-12-06 | 1.34 | 1.29 | +3.7% |
| 2023-08-30 | 1.21 | 1.13 | +7.3% |
| 2023-05-31 | 0.91 | 0.80 | +13.6% |
| 2023-03-01 | 1.15 | 1.04 | +10.6% |
| 2022-12-01 | 1.13 | 1.07 | +5.3% |
| 2022-08-31 | 1.03 | 1.01 | +1.9% |
| 2022-06-01 | 0.99 | 0.92 | +7.3% |
| 2022-03-02 | 0.90 | 0.88 | +2.0% |
| 2021-12-01 | 0.97 | 0.88 | +10.6% |
| 2021-09-01 | 0.94 | 0.86 | +9.0% |
| 2021-05-27 | 0.91 | 0.78 | +16.7% |
Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).
Peer comparison · Healthcare
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| VEEV ★ | $30B | 33.7 | 18.5 | 9.3 | 23.8 | 4.2 | 75.5% | 16.0% | 23.2% | 3.51% |
| LLY | $949B | 37.7 | 23.9 | 13.1 | 27.3 | 30.5 | 82.8% | 55.5% | 169.9% | 0.96% |
| UNH | $343B | 28.5 | 18.1 | 0.8 | 18.5 | 3.5 | 18.8% | 2.0% | 0.7% | 5.15% |
| JNJ | $537B | 25.8 | 17.5 | 5.6 | 16.6 | 6.6 | 68.0% | 9.9% | -52.9% | 2.33% |
| MRK | $286B | 32.6 | 12.1 | 4.3 | 11.2 | 6.2 | 76.7% | 4.9% | — | 4.92% |
| ABBV | $381B | 105.6 | 13.3 | 6.1 | 14.8 | -57.2 | 72.0% | 12.4% | -46.2% | 5.47% |
| PFE | $146B | 19.5 | 9.0 | 2.3 | 7.8 | 1.6 | 74.8% | 5.4% | -10.1% | 8.50% |
| TMO | $179B | 26.5 | 17.7 | 4.0 | 19.4 | 3.4 | 40.9% | 6.2% | 11.3% | 3.08% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Top institutional holders
Top-10 concentration: 33.03%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 11,558,875 | 7.09% |
| Vanguard Portfolio Management LLC | 7,376,031 | 4.52% |
| Vanguard Capital Management LLC | 6,670,318 | 4.09% |
| Alliancebernstein L.P. | 6,271,098 | 3.84% |
| Linonia Partnership LP | 4,924,626 | 3.02% |
| Principal Financial Group, Inc. | 4,141,545 | 2.54% |
| State Street Corporation | 3,608,655 | 2.21% |
| T. Rowe Price Investment Management, | 3,405,594 | 2.09% |
| Geode Capital Management, LLC | 3,312,734 | 2.03% |
| FMR, LLC | 2,613,526 | 1.60% |
Insider activity · 90d
No insider trades for VEEV in last 90d.
Analyst estimates
yfinanceConsensus: buy (mean 1.86667). Distribution requires FINNHUB_API_KEY.
SEC filings
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-05-04 | FORM 4 | view · |
| DEF 14A | 2026-05-04 | DEF 14A | view · |
| 8-K | 2026-04-20 | 8-K | view · |
| 4 | 2026-04-14 | FORM 4 | view · |
| 4 | 2026-04-09 | FORM 4 | view · |
| 4 | 2026-04-09 | FORM 4 | view · |
| 4 | 2026-04-09 | FORM 4 | view · |
| 4 | 2026-04-09 | FORM 4 | view · |
| 4 | 2026-04-09 | FORM 4 | view · |
| 4 | 2026-04-03 | FORM 4 | view · |
| 4 | 2026-04-03 | FORM 4 | view · |
| 4 | 2026-04-03 | FORM 4 | view · |
| 4 | 2026-04-03 | FORM 4 | view · |
| 4 | 2026-04-03 | FORM 4 | view · |
| 10-K | 2026-03-20 | 10-K | view · |
| 4 | 2026-03-09 | FORM 4 | view · |
| 8-K | 2026-03-04 | 8-K | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-01-15 | FORM 4 | view · |
| 4 | 2026-01-05 | FORM 4 | view · |
| 4 | 2026-01-05 | FORM 4 | view · |
| 4 | 2026-01-05 | FORM 4 | view · |
| 4 | 2026-01-05 | FORM 4 | view · |
| 4 | 2026-01-05 | FORM 4 | view · |
| 8-K | 2026-01-05 | 8-K | view · |
| 4 | 2025-12-11 | FORM 4 | view · |
| 8-K | 2025-12-11 | 8-K | view · |
| 4 | 2025-12-03 | FORM 4 | view · |
| 4 | 2025-12-02 | FORM 4 | view · |
| 4 | 2025-12-02 | FORM 4 | view · |
| 4 | 2025-12-02 | FORM 4 | view · |
| 4 | 2025-12-02 | FORM 4 | view · |
| 4 | 2025-12-02 | FORM 4 | view · |
| 4 | 2025-12-02 | FORM 4 | view · |
| 4 | 2025-12-02 | FORM 4 | view · |
| 10-Q | 2025-11-21 | 10-Q | view · |
| 8-K | 2025-11-20 | 8-K | view · |
| 8-K | 2025-11-18 | 8-K | view · |
| 4 | 2025-10-10 | FORM 4 | view · |
| 4 | 2025-10-09 | FORM 4 | view · |
| 4 | 2025-10-08 | FORM 4 | view · |
| 4 | 2025-10-03 | FORM 4 | view · |
| 4 | 2025-10-03 | FORM 4 | view · |
| 4 | 2025-10-03 | FORM 4 | view · |
| 4 | 2025-10-03 | FORM 4 | view · |
| 4 | 2025-10-03 | FORM 4 | view · |
| 4 | 2025-09-03 | FORM 4 | view · |
| 4 | 2025-09-03 | FORM 4 | view · |
| 4 | 2025-09-03 | FORM 4 | view · |
| 4 | 2025-09-03 | FORM 4 | view · |
| 4 | 2025-09-03 | FORM 4 | view · |
| 4 | 2025-09-03 | FORM 4 | view · |
| 4 | 2025-09-03 | FORM 4 | view · |
About
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies; Veeva PromoMats, an end-to-end content and digital asset management solution; and Veeva Crossix, an analytics platform for pharmaceutical brands. It also provides Veeva Data Cloud, such as Veeva OpenData, a customer reference data solution; Veeva Link, which provides deep data; Veeva Compass, which includes de-identified and longitudinal patient data; and Veeva CRM Pulse that provides access and multichannel engagement metrics. In addition, the company offers Veeva Development Cloud consisting of Veeva Clinical Platform, which advances clinical trial execution; Veeva Clinical Data Management that helps sponsors and CROs design and run trials; Veeva Safety, which unifies systems and processes; Veeva RIM that provides regulatory information management capabilities, as well as Veeva Quality Cloud, which i…